Association of Androgenetic Alopecia with a More Severe Form of COVID-19 Infection

March 2022 in “ Irish Journal of Medical Science ”

Dunja Veskovic, Tatjana Roš, Tijana Icin, Kristina Stepanovic, Nebojsa Janjic, Dusan Kuljancic, Sonja Sedlarevic, Dmitar Vlahovic

androgenetic alopecia androgen receptor Gabrin sign androgen levels AGA

TLDR Men with androgenetic alopecia and hypertension may experience more severe COVID-19.

This study examined the link between androgenetic alopecia (AGA) and COVID-19 severity in 208 male patients, focusing on androgen receptor expression. It found that the Gabrin sign, a marker of AGA, was associated with worse COVID-19 outcomes, indicating a potential connection between androgen levels and disease severity. Hypertension was also identified as a factor related to poor COVID-19 prognosis. The results suggest that both AGA and hypertension may contribute to more severe COVID-19 outcomes, highlighting the need for further research with larger sample sizes to better understand these associations.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

17 / 17 results

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations , February 2021 in “Cureus”

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

research COVID-19, Androgens, and Androgenic Alopecia

6 citations , December 2020 in “Dermatological reviews”

COVID-19 may worsen with androgens; anti-androgen drugs could help.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

Women with high androgen levels may have more severe COVID-19 symptoms.

Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

research Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

32 citations , July 2020 in “Journal of The American Academy of Dermatology”

AGA linked to worse COVID-19 outcomes in men.

research Male Balding Is a Major Risk Factor for Severe COVID-19

29 citations , July 2020 in “Journal of The American Academy of Dermatology”

Men with severe balding have a higher risk of getting very sick from COVID-19.

research Are Sex Discordant Outcomes in COVID-19 Related to Sex Hormones?

42 citations , June 2020 in “Seminars in Oncology”

Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations , May 2020 in “Journal of The American Academy of Dermatology”

Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.